scholarly journals Potential inheritance patterns of a prothrombin gene mutation in a 23-year-old female and ethical considerations of a positive diagnosis: a case report

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Hannah Brand

Background: Prothrombin, also called Factor II, is a blood clotting protein found in all individuals that is necessary to form blood clots. In most individuals, a balance between bleeding and blood clot formation occurs. However, in individuals with a mutation in the prothrombin gene, the balance is disrupted due to excess production of prothrombin which leads to an increase in blood clot formation (1). Inherited predispositions to blood clot formation are termed hereditary thrombophilia. Prothrombin G20210A mutations are one of the most common hereditary gene associations. Case Description: This report examines the case of a 23-year-old female who has tested positive for the prothrombin gene mutation. The individual has an extensive history of blood clots including 8 deep vein thromboses (DVTs), 4 pulmonary embolisms with one complete infarction, 4 superficial clots, and a miscarried pregnancy attributed to her thrombophilia. The individual has a significant family history of the mutation and takes Coumadin daily for prevention of further clots. Practical and Ethical Implications: Despite a strong familial history of blood clots and related hospitalizations, the parents of the case individual do not want to get their other children tested for the mutation for fear that the children will be denied insurance coverage in their futures. The case individual will likely continue to be on blood thinners indefinitely. This will affect many aspects of her life, including dental treatment, as she will be at an increased risk for bleeding.

2017 ◽  
Vol 23 (3) ◽  
pp. 607-617 ◽  
Author(s):  
Albe C. Swanepoel ◽  
Odette Emmerson ◽  
Etheresia Pretorius

AbstractCombined oral contraceptive (COC) use is a risk factor for venous thrombosis (VT) and related to the specific type of progestin used. VT is accompanied by inflammation and pathophysiological clot formation, that includes aberrant erythrocytes and fibrin(ogen) interactions. In this paper, we aim to determine the influence of progesterone and different synthetic progestins found in COCs on the viscoelasticity of whole blood clots, as well as erythrocyte morphology and membrane ultrastructure, in an in vitro laboratory study. Thromboelastography (TEG), light microscopy, and scanning electron microscopy were our chosen methods. Our results point out that progestins influence the rate of whole blood clot formation. Alterations to erythrocyte morphology and membrane ultrastructure suggest the presence of eryptosis. We also note increased rouleaux formation, erythrocyte aggregation, and spontaneous fibrin formation in whole blood which may explain the increased risk of VT associated with COC use. Although not all COC users will experience a thrombotic event, individuals with a thrombotic predisposition, due to inflammatory or hematological illness, should be closely monitored to prevent pathological thrombosis.


2001 ◽  
Vol 47 (9) ◽  
pp. 1597-1606 ◽  
Author(s):  
Armando Tripodi ◽  
Pier Mannuccio Mannucci

Abstract Until recently, laboratory diagnosis of thrombophilia was based on investigation of the plasmatic anticoagulant pathways to detect antithrombin, protein C, and protein S deficiencies and on the search for dysfibrinogenemia and anti-phospholipid antibodies/lupus anticoagulants. More recently, laboratory investigations have been expanded to include activated protein C (APC) resistance, attributable or not to the presence of the factor V Leiden mutation; hyperprothrombinemia attributable to the presence of the prothrombin gene mutation G20210A; and hyperhomocysteinemia attributable to impairment of the relevant metabolic pathway because of enzymatic and/or vitamin deficiencies. All of the above are established congenital or acquired conditions associated with an increased risk of venous and, more rarely, arterial thrombosis. Testing is recommended for patients who have a history of venous thrombosis and should be extended to their first-degree family members. Because most of the tests are not reliable during anticoagulation, it is preferable to postpone laboratory testing until after discontinuation of treatment. Whenever possible, testing should be performed by means of functional assays. DNA analysis is required for the prothrombin gene mutation G20210A. Laboratory diagnosis for anti-phospholipid antibodies/lupus anticoagulant should be performed by a combination of tests, including phospholipid-dependent clotting assays and solid-phase anti-cardiolipin antibodies. Hyperhomocysteinemia can be diagnosed by HPLC methods or by fluorescence polarization immunoassays.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5562-5562
Author(s):  
Alexandra Borst ◽  
Ibrahim Saber ◽  
Elizabeth Thames ◽  
Nimia Reyes ◽  
Michele Beckman ◽  
...  

Abstract Introduction There is no national surveillance system for venous thromboembolism (VTE) despite the associated morbidity, mortality and economic burden on the health care system. Estimates of the incidence of VTE in the U.S. range from 1-2 cases per 1,000 people, or approximately 300,000-600,000 cases per year. The estimated incidence in children is lower, ranging from 1-10 per 100,000, with the period of greatest risk for VTE < 1 year and in the teenage years. It has been observed that most children with VTE have a serious underlying medical condition. The contribution of inherited thrombophilia to VTE in children remains not well established. Methods All patients with VTE in Durham County, North Carolina (NC), were identified as part of a VTE Surveillance Project supported by the Centers for Disease Control and Prevention from April 2012 through March 2014. Surveillance included an information technology-based electronic medical record review of diagnosis and specific treatment codes combined with manual review of radiographic imaging and autopsy reports. De-identified data were collected from the three hospitals in the county (Duke, Duke Regional, and the Durham VAMC) and entered into a REDCap database for analysis. Results The estimated population of Durham County during the study period was ~268,000, and ~69,000 of these individuals were < 20 years of age (25.7%). There were a total of 726 new cases of VTE in the county during the study period, for an estimated overall annual incidence of 0.135% (1.35 cases per 1000 per year). Of the total cohort, 19 individuals were less than 25 years of age (Figure 1), but only 8 patients were younger than 20 years, for an estimated annual incidence of VTE in the pediatric subset of 0.006% (6 cases per 100,000 per year). All pediatric VTE cases were identified at Duke University Medical Center. Table 1 lists characteristics of the pediatric population identified. The majority of patients were in their teenage years (75%) and there were no infants. One patient had a prior history of VTE and was taking warfarin at the time of diagnosis. None of the patients received primary pharmacologic thromboprophylaxis. One patient with intracranial hemorrhage did not receive any anticoagulant therapy after diagnosis of a deep vein thrombosis (DVT). One patient was treated with argatroban because of a history of heparin-induced thrombocytopenia, and the remainder were treated with enoxaparin or heparin. None were treated with fibrinolytic therapy or implantation of an IVC filter. Three patients underwent a thrombophilia evaluation, and one was heterozygous for the prothrombin gene mutation. Table 1. Pediatric Patient Characteristics Age (yrs) Sex Race/Ethnicity VTE Event Diagnostic Imaging Prothrombotic Risk Factors Hemorrhagic Risk Factors 4 M White DVT MRI Hemoglobinopathy, CVC 5 M Hispanic DVT US CVC ICH, DIC 17 F White DVT; PE MRI;VQ Scan OCP, Prothrombin gene mutation 18 F White DVT US Immobility ICH 18 M African American DVT US CVC; relative immobility, trauma 19 M African American PE CT CrohnÕs disease, smoking 19 M African American DVT US Prior VTE; ?Protein S deficiency, obesity 19 F African American PE CT Contraceptive patch PE = pulmonary embolus, US = ultrasound, CT = computed tomography scan, VQ = ventilation/perfusion scan, MRI = magnetic resonance imaging, CVC = central venous catheter, OCP = oral contraceptive pill, ICH = intracranial hemorrhage, DIC = disseminated intravascular coagulation Discussion Although 25.7% of individuals living within Durham County, NC are < 20 years of age, this age group represents only ~1.1% of the total number of individuals identified with VTE. The incidence of pediatric VTE was approximately 6 per 100,000 per year, consistent with prior reports. VTE was more common in African Americans in the pediatric patients, which we have observed in all age groups in this surveillance study. Most patients were teenagers, and one or more acquired prothrombotic risk factors were present in all. We did not identify any infants (age < 1 year) in this study, likely reflecting the small sample size and geographic restriction of the study. The type of VTE events observed and initial treatment strategies were similar to adult patients studied. A more accurate assessment of pediatric VTE within a tertiary care academic medical center will need to capture patients from a broader geographic distribution to represent the referral patterns for these complex patients. Disclosures Ortel: Instrumentation Laboratory: Consultancy; Instrumentation Laboratory: Research Funding; Eisai: Research Funding; Daiichi Sankyo: Consultancy.


2014 ◽  
Vol 27 (3) ◽  
pp. 243-252 ◽  
Author(s):  
Emily M. Armstrong ◽  
Jessica M. Bellone ◽  
Lori B. Hornsby ◽  
Sarah Treadway ◽  
Haley M. Phillippe

Pregnancy is associated with an increased risk of venous thromboembolism (VTE), with a reported incidence ranging from 0.49 to 2 events per 1000 deliveries. Risk factors include advanced maternal age, obesity, smoking, and cesarian section. Women with a history of previous VTE are at a 4-fold higher risk of recurrent thromboembolic events during subsequent pregnancies. Additionally, the presence of concomitant thrombophilia, particularly factor V Leiden (homozygosity), prothrombin gene mutation (homozygosity), or antiphospholipid syndrome (APS), increases the risk of pregnancy-related VTE. Low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) are the drugs of choice for anticoagulation during pregnancy. LMWH is preferred due to ease of use and lower rates of adverse events. Women with high thromboembolic risk particularly those with a family history of VTE should receive antepartum thromboprophylaxis. Women with low thromboembolic risk or previous VTE caused by a transient risk factor (ie, provoked), who have no family history of VTE, may undergo antepartum surveillance. Postpartum anticoagulation can be considered in women with both high and low thromboembolic risk.


2009 ◽  
Vol 3 (1) ◽  
pp. 147-151 ◽  
Author(s):  
F.M. Attia ◽  
D.P. Mikhailidis ◽  
S.A. Reffat

Aim: The pathogenesis of deep venous thrombosis (DVT) involves an interaction between hereditary and acquired factors. Prothrombin gene mutation is one of the hereditary risk factors. We evaluated the frequency of the prothrombin gene mutation in patients with DVT and its relation to oral warfarin anticoagulant therapy response.Methods: Prothrombin gene mutation was looked for in 40 DVT patients with poor response to warfarin. The results were compared with 40 DVT patients with a normal response to warfarin and 30 healthy blood donors. Blood samples were also assessed for protein C, protein S, anti-thrombin III and anticardiolipin antibodies (ACA) levels.Results: Prothrombin gene mutation was found in normal and poor DVT responders (6/40 and 13/40, respectively; p = NS) as well as in healthy controls (1/30). Patients with recurrent DVT or a family history of DVT were significantly (p<0.0001) more likely to have the prothrombin mutation than other DVT patients. Non prothrombin abnormalities (protein C, anti-thrombin III and ACA) were more common in poor responders than controls (p<0.0037) as were ACA (p<0.034).Conclusions: Prothrombin gene mutation is present in several DVT patients, especially those with recurrent DVT or a family history of DVT. This mutation may contribute to a poor response to warfarin.


2002 ◽  
Vol 107 (1-2) ◽  
pp. 7-11 ◽  
Author(s):  
I Gouin-Thibault ◽  
R Arkam ◽  
S Nassiri ◽  
A de la Tourette ◽  
J Conard ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Aibek E. Mirrakhimov ◽  
Erwin Velasquez Kho ◽  
Alaa Ali

87 year old Caucasian female with chronic painless non-healing ulcers over malleoli was admitted to the hospital. On a physical examination, there were two bilateral and laterally located malleoli ulcers with no discharge. A thorough work up was done: lower extremities venous and arterial Doppler ultrasound did not show any evidence of venous and arterial disease respectively. Heterozygous G20210A Prothrombin gene mutation was found, and the patient was started on anticoagulation. This case reports highlights a possibility of a painless livedoid vasculopathy presentation in a patient without significant past thrombotic events. Therefore, it is important to consider livedoid vasculopathy in the differential in a patient with painless ulcerative, atrophic and/or nodular skin lesions over the shins and malleoli.


2000 ◽  
Vol 118 (4) ◽  
pp. A1345
Author(s):  
Neil Haslam ◽  
Standen R. Graham ◽  
Jonathon L. Brown ◽  
Roland M. Valori ◽  
Christopher S. Probert

Sign in / Sign up

Export Citation Format

Share Document